Feedback / Questions
CHS-3351 (ranibizumab biosimilar) - Coherus
CHS-3351: Initiation of clinical development in 2018
(36th Annual J.P. Morgan Healthcare Conference, Coherus)
Jan 10, 2018
New trial
•
Biosimilar
https://jpmorgan.metameetings.net/events/healthcare18/sessions/13298-coherus-biosciences-inc/presentation_slides
Jan 10, 2018
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious